Severe dementia: diagnosis, patient management, prevention of complications
Suggested citation:
Lokshina AB. [Severe dementia: diagnosis, patient management, prevention of complications]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2017;(4):53-60. Russian
Timely diagnosis and the early start of therapy for cognitive impairments (CI) are extremely important. Unfortunately, there is a serious problem of belated CI diagnosis (it is often diagnosed only at the stage of severe dementia). The article discusses the current CI classification by the severity level. Special attention is paid to clinical symptoms, diagnostic criteria, and the basic principles of managing dementia patients. The differences in the severity levels of dementia are discussed in detail; special attention is given to severe dementia. The demand for structuring the clinical assessment of the state of cognitive functions and of the CI influence on daily activity is emphasized. For this purpose, it is recommended that special clinical scales listing cognitive symptoms that are most typical of various stages of cognitive deficit are used. The Clinical Dementia Rating (CDR) Scale is one of the well-proved scales. The main approaches for managing patients with severe dementia, including modern drugs for correction of CI and behavioral disorders, are discussed. The possibility and advisability are discussed for treating severe dementia with acetylcholinesterase inhibitors and/or a competitive blocker of the NMDA-receptor, memantine. Special attention is paid to behavioral disorders in patients with severe dementia. These disorders require both the medication correction and psychological support from relatives. The critical significance is emphasized for the proper patient care and for the correction of associated disorders, including pelvic disorders. Neurogenic inappropriate urination often accompanies the manifestations of CI and other neuropsychiatric disorders in patients with severe dementia. The main groups of medications that are used for drug therapy of this condition, as well as possibilities for using modern absorbents and care agents, are discussed.
1. Yakhno NN. [Cognitive impairment in neurological clinical practice]. Nevrologicheskii zhurnal. 2006;11(S1):4-12. (In Russian) 2. Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii [Dementias]. Moscow: MedPress-inform; 2011. 272 p. 3. Zakharov VV, Yakhno NN. Kognitivnye rasstroistva v pozhilom i starcheskom vozraste [Cognitive frustration at advanced and senile age.]. Moscow; 2005. 71 p. (In Russian) 4. Damulin IV. Bolezn' Al'tsgeimera i sosudistaya dementsiya [Alzheimer's disease and vascular dementia]. Yakhno NN, editor. Moscow; 2002. 85 p. (In Russian) 5. Lokshina AB, Zakharov VV. [Cognitive disorders in general clinical practice]. Vrach. 2009;(4):21-5. (In Russian) 6. Yakhno NN, Zakharov VV, Lokshina AB. Narusheniya pamyati i vnimaniya v pozhilom vozraste. Zhurnal nevrologii ipsikhiatrii im. S.S. Korsakova. 2006;106(2):58-63. (In Russian) 7. Damulin IV, Yakhno NN. Degenerativnye zabolevaniya s kognitivnymi rasstroistvami. V kn.: Bolezni nervnoi sistemy [Degenerate diseases with cognitive frustration. In: Diseases of nervous system.]. Yakhno NN, editor. Moscow: Meditsina; 2005. Vol. 1. P. 192-207. (In Russian) 8. MKB-10. Mezhdunarodnaya statisticheskaya klassifikatsiya boleznei iproblem, svyazannykh so zdorov'em, 10 peresmotr [MKB-10. The international statistical classification of diseases and the problems connected with health, the 10th revision]. Zheneva: VOZ, 1995. Vol. 1. P. 320, 315, 317, 510-511. (In Russian) 9. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-4. DOI: http://dx.doi.org/10.1212/WNL.43.11.2412-a. 10. Erkinjuntti T, Roman G, Gauthier S, et al. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke. 2004;35(4):1010-7. DOI: http://dx.doi.org/10.1161/01.STR.0000120731. 88236.33. Epub 2004 Mar 4. 11. Lovenstone S, Gauthier S. Management of dementia. London: Martin Dunitz; 2001. 12. Wilcock GK, Bucks RS, Rockwood K. Diagnosis and management of dementia. A manual for memory disorders team. Oxford, N.Y.: Oxford University Press; 1999. P. 251. 13. Zakharov VV, Yakhno NN. [Modern aspects of pharmacotherapy of dementia]. Nevrologicheskiy zhurnal. 2006;11(2):3-6. (In Russian) 14. Gavrilova SI, Kolykhalov IV, Kalynia B, Selezneva ND. [Galantamine (reminyl) in the treatment of severe alzheimer's disease]. Zhurnal nevrologii ipsikhiatrii im. S.S. Korsakova. 2009;109 (7):57-61. (In Russian) 15. Gavrilova SI, Kalyn YaB, Selezneva ND, et al. [Glutamatergichesky therapy of Alzheimer's disease at a stage of moderate and heavy and heavy dementia: results of 26-week research of efficiency and safety of the preparation «Akatinol Memantin»]. Psikhiatriya i psikhofarmakoterapiya. 2005;7(2):72-6. (In Russian) 16. Kolykhalov IV, Gavrilova SI, Kalyn IaB, et al. [Efficacy, safety and tolerability of a single dose of akatinol memantine in comparison to two-doses in patients with moderately expressed and moderately severe dementia in Alzheimer's disease]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(1):35-9. (In Russian) 17. Yakhno NN, Preobrazhenskaya IS, Zakharov VV, Mkhitaryan EA. [Efficiency akatinola memantina at patients with nedementny cognitive frustration]. Results of multicenter clinical supervision. Nevrologicheskiy zhurnal. 2010;15(2):52—8. (In Russian) 18. Uspenskaya OV, Yakhno NN. [The impact of memantine on cognitive functions in patients with amnestic type of mild cognitive impairment (clinical-psychological and neurochemical study)]. Nevrologicheskiy zhurnal. 2009;14(3):37-40. (In Russian) 19. Parfenov VA. [Neuгological aspects of urinary incontinence in the elderiy]. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;(1):34-8. (In Russian). DOI: http://dx.doi.org/10.14412/ 2074-2711-2013-2395. 20. Pizova NV. [Outpatient management afteг seveгe stгoke with dementia]. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;(4):78-83. (In Russian). DOI: http://dx.doi.oig/10.14412/ 2074-2711-2013-24б0. 21. Vorob'ev PA, Krasnova LS, Shustov AG, et al. Kliniko-ekonomicheskiy analiz effektivnosti ispol'zovaniyapodguznikov MoliCare® Premium extra soft (Molikar Premium ekstra soft) dlyaprofilaktiki razvitiya dermatita i prolezhney u nepodvizhnykh bol'nykh s nederzhaniem mochi. Vsb.: Prolezhni. Ekonomika iprofilaktika [The Kliniko-ekonomichesky analysis of efficiency of use of diapers of MoliCare® Premium extra soft (Molikar Premium extra software) for prevention of development of dermatitis and decubi-tuses at motionless patients with an urine incontience. On Saturday : Decubituses. Economy and prevention]. Vorob'eva PA, Krasnova LS, redaktory. Moscow: N'yudiamed; 2012. P. 34-99. (In Russian)
DOI: http://dx.doi.org/10.24411/1560-957X-2017-1%25x
Article Metrics
Metrics powered by PLOS ALM